Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914290 · ClinicalTrials.gov registry record · Phase 2
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Phase 2 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00914290: Completed Phase 2 study, sponsored by Impax Laboratories.
NCT00914290 is a Phase 2 study that has completed, run by Impax Laboratories. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00914290, a Phase 2 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).
Interventions
- DRUG Baclofen IR
- DRUG IPX056
- DRUG Placebo IPX056
- DRUG Placebo IR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00914290 record still lists
NCT00914290 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 4 interventions - of which Baclofen IR is the first listed.
NCT00914290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00914290 about?
NCT00914290 is a clinical study titled "A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis". To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).
What is the current status of trial NCT00914290?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2009-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00914290?
The interventions under investigation include: Baclofen IR (DRUG), IPX056 (DRUG), Placebo IPX056 (DRUG), Placebo IR (DRUG).
Who is sponsoring clinical trial NCT00914290?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00914290's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia